Ida Skarping1, Daniel Förnvik2, Uffe Heide-Jørgensen3, Hanna Sartor4, Per Hall5,6, Sophia Zackrisson4, Signe Borgquist7,8. 1. Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Skane University Hospital, Barngatan 4, 221 85, Lund, Sweden. ida.skarping@med.lu.se. 2. Department of Translational Medicine, Medical Radiation Physics, Lund University, Skane University Hospital, Malmö, Sweden. 3. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Translational Medicine, Diagnostic Radiology, Lund University, Skane University Hospital, Lund and Malmö, Sweden. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden. 6. Department of Oncology, Södersjukhuset, Stockholm, Sweden. 7. Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Skane University Hospital, Barngatan 4, 221 85, Lund, Sweden. 8. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Abstract
PURPOSE: Personalized cancer treatment requires predictive biomarkers, including image-based biomarkers. Breast cancer (BC) patients receiving neoadjuvant chemotherapy (NACT) are in a clinically vulnerable situation with the tumor present. This study investigated whether mammographic density (MD), assessed pre-NACT, is predictive of pathological complete response (pCR). METHODS: A total of 495 BC patients receiving NACT in Sweden 2005-2019 were included, merged from two different cohorts. Cohort 1 was retrospectively collected (n = 295) and cohort 2 was prospectively collected (n = 200). Mammograms were scored for MD pre-NACT according to the Breast Imaging-Reporting and Data System (BI-RADS), 5th Edition. The association between MD and accomplishing pCR post-NACT was analyzed using logistic regression models-for the whole cohort, stratified by menopausal status, and in different St. Gallen surrogate subtypes. RESULTS: In comparison to patients with low MD (BI-RADS a), the multivariable-adjusted odds ratio (OR) of accomplishing pCR following NACT was on a descending scale: 0.62 (95% confidence interval (CI) 0.24-1.57), 0.38 (95% CI 0.14-1.02), and 0.32 (95% CI 0.09-1.08) for BI-RADS b, c, and d, respectively. For premenopausal patients selectively, the corresponding point estimates were lower, although wider CIs: 0.31 (95% CI 0.06-1.62), 0.24 (95% CI 0.04-1.27), and 0.13 (95% CI 0.02-0.88). Subgroup analyses based on BC subtypes resulted in imprecise estimates, i.e., wide CIs. CONCLUSIONS: It seemed as though patients with higher MD at baseline were less likely to reach pCR after NACT-a finding more pronounced in premenopausal women. Larger multicenter studies are needed to enable analyses and interpretation for different BC subtypes.
PURPOSE: Personalized cancer treatment requires predictive biomarkers, including image-based biomarkers. Breast cancer (BC) patients receiving neoadjuvant chemotherapy (NACT) are in a clinically vulnerable situation with the tumor present. This study investigated whether mammographic density (MD), assessed pre-NACT, is predictive of pathological complete response (pCR). METHODS: A total of 495 BC patients receiving NACT in Sweden 2005-2019 were included, merged from two different cohorts. Cohort 1 was retrospectively collected (n = 295) and cohort 2 was prospectively collected (n = 200). Mammograms were scored for MD pre-NACT according to the Breast Imaging-Reporting and Data System (BI-RADS), 5th Edition. The association between MD and accomplishing pCR post-NACT was analyzed using logistic regression models-for the whole cohort, stratified by menopausal status, and in different St. Gallen surrogate subtypes. RESULTS: In comparison to patients with low MD (BI-RADS a), the multivariable-adjusted odds ratio (OR) of accomplishing pCR following NACT was on a descending scale: 0.62 (95% confidence interval (CI) 0.24-1.57), 0.38 (95% CI 0.14-1.02), and 0.32 (95% CI 0.09-1.08) for BI-RADS b, c, and d, respectively. For premenopausal patients selectively, the corresponding point estimates were lower, although wider CIs: 0.31 (95% CI 0.06-1.62), 0.24 (95% CI 0.04-1.27), and 0.13 (95% CI 0.02-0.88). Subgroup analyses based on BC subtypes resulted in imprecise estimates, i.e., wide CIs. CONCLUSIONS: It seemed as though patients with higher MD at baseline were less likely to reach pCR after NACT-a finding more pronounced in premenopausal women. Larger multicenter studies are needed to enable analyses and interpretation for different BC subtypes.
Entities:
Keywords:
Breast cancer; Breast density; Mammography; Neoadjuvant chemotherapy
Authors: Nehmat Houssami; Petra Macaskill; Gunter von Minckwitz; Michael L Marinovich; Eleftherios Mamounas Journal: Eur J Cancer Date: 2012-07-03 Impact factor: 9.162
Authors: H J Burstein; G Curigliano; S Loibl; P Dubsky; M Gnant; P Poortmans; M Colleoni; C Denkert; M Piccart-Gebhart; M Regan; H-J Senn; E P Winer; B Thurlimann Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Cecilia W Huo; Grace Chew; Prue Hill; Dexing Huang; Wendy Ingman; Leigh Hodson; Kristy A Brown; Astrid Magenau; Amr H Allam; Ewan McGhee; Paul Timpson; Michael A Henderson; Erik W Thompson; Kara Britt Journal: Breast Cancer Res Date: 2015-06-04 Impact factor: 6.466
Authors: Ida Skarping; Daniel Förnvik; Uffe Heide-Jørgensen; Hanna Sartor; Per Hall; Sophia Zackrisson; Signe Borgquist Journal: Breast Date: 2020-06-04 Impact factor: 4.380
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976
Authors: Kimberly A Bertrand; Rulla M Tamimi; Christopher G Scott; Matthew R Jensen; V Pankratz; Daniel Visscher; Aaron Norman; Fergus Couch; John Shepherd; Bo Fan; Yunn-Yi Chen; Lin Ma; Andrew H Beck; Steven R Cummings; Karla Kerlikowske; Celine M Vachon Journal: Breast Cancer Res Date: 2013-11-04 Impact factor: 8.408
Authors: C Cullinane; A O Brien; A Shrestha; E O Hanlon; J Walshe; J Geraghty; D Evoy; D McCartan; E McDermott; R Prichard Journal: Breast Cancer Res Treat Date: 2022-05-23 Impact factor: 4.624